CD274 and small cell lung carcinoma: Li et al. (Li et al., 2023) compared the efficacy of six different PD-1/PD-L1 inhibitors, either alone or in combination with chemotherapy, in the treatment of extensive-stage small cell lung cancer, including PD-L1 inhibitor (atezolizumab or durvalumab or adebrelimab) plus chemotherapy versus chemotherapy alone, and PD-1 inhibitor (pembrolizumab or nivolumab or serplulimab) plus chemotherapy versus chemotherapy alone.